Business Description
Dr Reddy's Laboratories Ltd
ISIN : US2561352038
Share Class Description:
STU:RDDA: ADRTotal Employee Number:
27,527Description
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.13 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | 1.08 | |||||
Interest Coverage | 8.66 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.05 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.9 | |||||
3-Year EBITDA Growth Rate | 2 | |||||
3-Year EPS without NRI Growth Rate | -3.9 | |||||
3-Year FCF Growth Rate | -23 | |||||
3-Year Book Growth Rate | 17.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.79 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.65 | |||||
9-Day RSI | 20.43 | |||||
14-Day RSI | 27.34 | |||||
3-1 Month Momentum % | 9.57 | |||||
6-1 Month Momentum % | 13.51 | |||||
12-1 Month Momentum % | 4.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.9 | |||||
Quick Ratio | 1.39 | |||||
Cash Ratio | 0.52 | |||||
Days Inventory | 181.69 | |||||
Days Sales Outstanding | 109.74 | |||||
Days Payable | 83.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.73 | |||||
Dividend Payout Ratio | 0.21 | |||||
3-Year Dividend Growth Rate | 10.1 | |||||
Forward Dividend Yield % | 0.73 | |||||
5-Year Yield-on-Cost % | 1.3 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -1.45 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53 | |||||
Operating Margin % | 10.89 | |||||
Net Margin % | 10 | |||||
EBITDA Margin % | 20.13 | |||||
FCF Margin % | 2.86 | |||||
OCF Margin % | 12.55 | |||||
ROE % | 8.99 | |||||
ROA % | 5.96 | |||||
ROIC % | 7.21 | |||||
3-Year ROIIC % | -2.43 | |||||
ROC (Joel Greenblatt) % | 22.59 | |||||
ROCE % | 11.35 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 28.94 | |||||
Forward PE Ratio | 25.57 | |||||
PE Ratio without NRI | 30.37 | |||||
Shiller PE Ratio | 27.61 | |||||
Price-to-Owner-Earnings | 41.53 | |||||
PEG Ratio | 1.68 | |||||
PS Ratio | 2.89 | |||||
PB Ratio | 2.5 | |||||
Price-to-Tangible-Book | 3.59 | |||||
Price-to-Free-Cash-Flow | 103.93 | |||||
Price-to-Operating-Cash-Flow | 23.26 | |||||
EV-to-EBIT | 20.93 | |||||
EV-to-Forward-EBIT | 18.76 | |||||
EV-to-EBITDA | 14.27 | |||||
EV-to-Forward-EBITDA | 13.79 | |||||
EV-to-Revenue | 2.87 | |||||
EV-to-Forward-Revenue | 2.65 | |||||
EV-to-FCF | 103.24 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 1.64 | |||||
Price-to-DCF (Earnings Based) | 1.52 | |||||
Price-to-DCF (FCF Based) | 10.2 | |||||
Price-to-Median-PS-Value | 0.88 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.76 | |||||
Price-to-Graham-Number | 2.2 | |||||
| Price-to-Net-Current-Asset-Value | 8.94 | |||||
Earnings Yield (Greenblatt) % | 4.78 | |||||
FCF Yield % | 0.96 | |||||
Forward Rate of Return (Yacktman) % | 19.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Dr Reddy's Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,115.302 | ||
| EPS (TTM) (€) | 0.378 | ||
| Beta | -0.1139 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.21 | ||
| Volatility % | 16.88 | ||
| 14-Day RSI | 27.34 | ||
| 14-Day ATR (€) | 0.352231 | ||
| 20-Day SMA (€) | 11.02 | ||
| 12-1 Month Momentum % | 4.13 | ||
| 52-Week Range (€) | 9.75 - 13.6 | ||
| Shares Outstanding (Mil) | 833 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dr Reddy's Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dr Reddy's Laboratories Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-01-21 19:30 | In 175 days | ||
| Third quarter earnings results for 2027 | 2027-01-21 | In 173 days | ||
| Second quarter earnings conference call for 2027 | 2026-10-23 19:30 | In 85 days | ||
| Second quarter earnings results for 2027 | 2026-10-23 | In 83 days | ||
| General meeting for 2026 | 2026-07-23 11:00 | 10.90 (+2.83%) | ||
| First quarter earnings conference call for 2027 | 2026-07-22 19:30 | 10.90 (+0.93%) | ||
| First quarter earnings results for 2027 | 2026-07-22 | 10.90 (+0.93%) | ||
| USD 0.083412 Cash Dividend | 2026-07-09 | 12.30 (-3.15%) | ||
| Annual report for 2026 | 2026-05-29 | 11.50 (-0.86%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-12 10:00 | 11.00 (+0.00%) |
Show
Entries
Dr Reddy's Laboratories Ltd Frequently Asked Questions
What is Dr Reddy's Laboratories Ltd(STU:RDDA)'s stock price today?
The current price of STU:RDDA is €10.10. The 52 week high of STU:RDDA is €13.60 and 52 week low is €9.75.
When is next earnings date of Dr Reddy's Laboratories Ltd(STU:RDDA)?
The next earnings date of Dr Reddy's Laboratories Ltd(STU:RDDA) is 2026-10-23 Est..
Does Dr Reddy's Laboratories Ltd(STU:RDDA) pay dividends? If so, how much?
The Dividend Yield % of Dr Reddy's Laboratories Ltd(STU:RDDA) is 0.73% (As of Today), Highest Dividend Payout Ratio of Dr Reddy's Laboratories Ltd(STU:RDDA) was 0.4. The lowest was 0.11. And the median was 0.16. The Forward Dividend Yield % of Dr Reddy's Laboratories Ltd(STU:RDDA) is 0.73%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Dr Reddy's Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers